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Abstract 
Aims 
Computing the number of alcohol-attributable deaths requires a series of hypotheses. Using 
French data for 2006, the potential biases are reviewed and the sensitivity of estimates to 
various hypotheses evaluated. 
Methods 
Self-reported alcohol consumption data were derived from large population-based surveys. 
The risks of occurrence of diseases associated with alcohol consumption and relative risks 
for all-cause mortality were obtained through literature searches. All-cause and cause-
specific population alcohol-attributable fractions (PAAFs) were calculated. In order to account 
for potential under-reporting, the impact of adjustment on sales data was tested. The 2006 
mortality data were restricted to people aged between 15 and 75 years. 
Results 
When alcohol consumption distribution was adjusted for sales data, the estimated number of 
alcohol-attributable deaths, the sum of the cause-specific estimates, was 20255. Without 
adjustment, the estimate fell to 7158. 
Using an all-cause mortality approach, the adjusted number of alcohol-attributable deaths 
was 15950, while the non-adjusted estimate was a negative number. 
Other methodological issues such as computation based on risk estimates for all causes for 
'all countries' or only 'European countries', also influenced the results, but to a lesser extent. 
Discussion 
The estimates of the number of alcohol-attributable deaths varied greatly, depending on the 
hypothesis used. The most realistic and evidence-based estimate seems to be obtained by 
adjusting the consumption data for national alcohol sales, and by summing the cause-
specific estimates. However, interpretation of the estimates must be cautious in view of their 
potentially large imprecision. 
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Introduction 
In many countries, alcohol drinking is a major public health issue. As is the case for 
estimation of the impact of tobacco smoking on a population (1), the number of alcohol-
attributable deaths has been used to evaluate the health burden of alcohol (2-9). Some 
studies have specifically focused on cancer attributable to alcohol (10). 
Most of the recent evaluations of the dose-response relationship between alcohol 
consumption and cancer suggest a quasi-linear association (11, 12). However, a non-
monotonous J-shaped association was evidenced for coronary heart disease and stroke (13-
15), diabetes (16) and all-cause mortality (17, 18), with a lower risk for low alcohol 
consumption, compared to abstinence. Due to methodological concerns about the definition 
of abstainers (19, 20), the exact J-shaped relationship is still under debate (21). Thus, some 
studies, including a Swedish study (8), pointed to a negative impact of alcohol consumption 
on mortality. 
The method used by the various authors to calculate the proportion of alcohol-attributable 
deaths is simple and homogeneous, and based on the availability of relative risks determined 
by large meta-analyses and alcohol consumption prevalence data derived from population–
based surveys. The proportions were then applied to the number of deaths recorded in the 
national statistics. The simplicity of the calculation masks a large number of underlying 
hypotheses that are generally not taken into account in the estimation process. 
One important hypothesis consists in the transferability of relative risks estimated from 
observational studies conducted on incident cases to death statistics (11, 12, 14, 16, 22, 23). 
For example, for the association between smoking and lung cancer, the relative risk may be 
used on either incidence or mortality data in a straightforward procedure, due to the high 
fatality of lung cancer. For other disease sites with higher survivals, the transfer of relative 
risk could be a source of biases and mask competitive risks among the various causes 
considered. 
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Another major hypothesis concerns the measurement of alcohol consumption in surveys: 
self-reported consumption is usually greatly underestimated (24, 25). Hence, various authors 
have suggested using a correction factor based on alcohol sales data (5, 24, 26). However, 
this adjustment may be misleading and give rise to a different consumption scale (reported 
vs. sold consumption) for relative risk estimates and population alcohol consumption 
incidence (27). The impact of the correction has rarely been evaluated (24). 
The objective of this paper is to describe and test the impact of the various hypotheses 
underlying the computation of attributable fractions on the estimates of the number of 
alcohol-attributable deaths. French data have been used to illustrate the methodological 
issues and evaluate the number of alcohol-attributable deaths in France in 2006, by gender 
and by cause of death. 
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Methods 
Population Alcohol-Attributable Fraction (PAAF) 
Levin’s formula (28), generalized for multiple categories (n) of risk, was applied: 
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in which RRi and Pi are the relative risks and prevalence for the i
th category of alcohol 
consumption. 
Variances of the PAAF were estimated by the delta method (29), with relative risk variance 
considered to be log-normally distributed and prevalence of alcohol consumption to be 
binomially distributed. 
The main methodological problem relative to this widely employed formula resides in the 
choice of RRi (diseases and relative risks) and Pi (consumption data). 
Among the methodological problems related to the relative risks, the choice between a 
cause-specific approach and an all-cause approach was considered. As a sensitivity 
analysis, the all-cause results obtained by considering the ‘all countries’ relative risk 
estimates and those obtained by considering the ‘European countries’ relative risk estimates 
were compared. 
Among the methodological problems related to consumption data, the need to adjust the 
data on alcohol sales data was considered. As a sensitivity analysis, a lag time between 
alcohol consumption and death, and the number of consumption categories (n) were also 
considered. 
Choice of diseases and relative risks 
Two methods of calculating the total number of alcohol-attributable deaths were compared.  
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In the first method, each cause of death was analyzed separately. Only established causes 
of death associated with alcohol consumption were included, using the list compiled by 
Jürgen Rehm (30). The PAAFs were set at 100% for by-definition alcohol-attributable 
causes. For the other causes, cause-specific relative risks expressed as risk by category of 
alcohol consumption in grammes per day were used. The relative risks were obtained from 
recent meta-analyses (11, 12, 14, 16, 22, 23, 26, 31) (table 1). When several meta-analyses 
were available, the most recent estimates including the greatest number of studies were 
considered. 
The second approach considered overall mortality and was only based on the relative risk of 
all-cause mortality. The analytical expression of the association between alcohol 
consumption and all-cause mortality was taken from the meta-analysis by Di Castelnuovo et 
al. (18): 
)clog(cc)RRlog( s,2s,1s,c  , 
in which 'c' is the consumption level, 'RRc,s' the relative risk of death for consumption level 'c' 
in grammes of pure alcohol per day, compared to the abstinent level, 's' sex, and 'β1,s' and 
'β2,s' the parameters that enable estimation of a J-shaped curve. 
The parameters 'β1,s' and 'β2,s' were chosen from the estimates generated by 'all countries' 
studies. In sensitivity analyses, the 'European countries' model was also considered since it 
is probably affected by less bias when applied to French data, but has greater variability. 
 
Alcohol consumption data 
Two large French surveys, representative of the general population, constituted the sources 
of the consumption data. The alcohol questionnaires in those surveys were based on the 
AUDIT-C questionnaire validated by WHO (32). The measurement method is of the quantity-
frequency type and targets the preceding 12 months. Other surveys had been conducted in 
France in previous years, but using different methodologies and questionnaires. Thus, even 
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though a greater lag time could have been used, doing so would have introduced 
uncontrolled comparability issues. 
The 2002 ESPS survey (33) included 13,000 subjects aged less than 75 years. The 2005 
Health Survey (34) included 29,000 subjects aged between 15 and 75 years. For each 
subject, alcohol consumption expressed in grammes of pure alcohol per day was deduced 
from the number of drinks per day. One drink was considered to contain 10 g of pure alcohol. 
The abstainer category was defined as subjects that had not drunk any alcohol at all in the 
preceding year. According to the 2005 Health survey, about 40% of last-year abstainers were 
lifetime abstainers. It was not possible to separate former heavy drinkers from very 
occasional drinkers (less than once per year) in that group with our data. 
 
Adjusted vs. non-adjusted consumption data 
As expected, in both surveys, there was a marked discrepancy between the reported 
average consumption (about 6.2 g/day) and the average calculated from the French alcohol 
sales statistics reported to the tax authorities (30.0 g/day in 2002). 
As described in previous studies (5, 24), for a subject 'j', adjusted alcohol consumption ( adj
jC ) 
was calculated as follows: 
C
S
CC j
adj
j
 , in which Cj is the consumption for a subject j calculated from the general 
population survey, C  is the mean consumption calculated from the general population 
survey and S is the mean consumption calculated from the sales data. The impact of so 
doing on the PAAF was investigated subsequently. 
 
Alcohol prevalence and relative risks 
The logarithms of the relative risk estimates were linearly interpolated in order to fit the 
consumption categories. 
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Lag time between adjusted consumption data and mortality 
The survey conducted in 2002 enabled a lag time of 4 years for chronic disease and for all-
cause mortality. Data from the 2005 survey enabled a minimal lag time for causes of death 
immediately related to recent alcohol consumption, such as violent death, to be considered. 
For chronic disease, it is likely that the alcohol related deaths from 2006 are attributable to 
older consumptions than those reported in the study. Given that alcohol consumption in 
France has been falling for 20 years (from 36.9 g/day in 1986 to 27.9 g/day in 2006), it may 
lead to underestimation of the related PAAFs. A sensitivity analysis thus estimated the 
impact of using a 20-year lag between alcohol consumption based on sales data and deaths 
due to chronic diseases. 
 
Choice of the number of consumption categories (n) 
If the association between the risk of death and alcohol consumption is considered to be 
linear, then, for all consumption categories i: 
ii CRR  , in which iC  is the mean consumption for the i
th category and β the linear 
association. 
Substituting for RRi in the PAAF formula gives: 
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 , in which C is the mean overall consumption. 
In consequence, for the linear association, the estimated PAAF is independent of the number 
of consumption categories. 
However, for all-cause mortality, stroke, coronary heart disease and diabetes, the J-shaped 
association is far from a linear trend. Thus, the PAAF estimate is sensitive to the number of 
categories selected (35). As a default scenario, 6 categories were used and the impact of 
using 4 and 10 categories was evaluated. 
 
Age groups considered 
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In most of the studies, the relative risks were already age-adjusted. The relative risks of the 
incidence of several diseases related to alcohol consumption were generally calculated for a 
middle-aged population, without considering potential competitive causes of deaths. The 
reported alcohol consumption is quasi-null for the population aged under 15 years. Thus, 
alcohol sales data are generally considered to represent the population aged 15 years and 
over. 
Therefore, the main calculations presented in this study were limited to subjects aged 
between 15 and 75 years. In order to obtain estimates comparable to those of published 
studies, the overall results for all ages have also been presented. 
 
Years of Potential Life Lost (YPLL) attributable to alcohol 
The YPLL was defined as the remaining life expectancy at the age of death (36). 
For a given disease, the number of alcohol-attributable deaths and number of alcohol-
attributable YPLL were calculated as the product of the PAAF and the total number of deaths 
and the total number of YPLL, respectively. 
In the cause-specific approach, the total death PAAF was calculated as the sum of cause-
specific alcohol-attributable deaths divided by the all-cause number of deaths. The total 
YPLL PAAF was calculated in the same manner. 
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Results 
Alcohol consumption 
The prevalence of low alcohol intakes, less than 20 g/day, was very high for both genders in 
the non-adjusted data of the ESPS 2002 survey (figure 1). Abstinence was more prevalent 
among women. 
When the ESPS 2002 survey data were adjusted for 2002 consumption, equivalent to 
multiplying all the consumptions by almost 5, the distribution extended further right (figure 1). 
Very similar alcohol distributions were observed in the 2005 Health survey. 
Cause-specific approach 
Population Alcohol-Attributable Fractions (PAAFs) 
Cause-specific PAAFs were strongly dependent on adjustment or non-adjustment for alcohol 
sales data (table 2).  
When adjusted for 2002 alcohol sales data, the PAAFs were generally positive, except for 
diabetes and ischaemic heart disease for women. However, many PAAF were not 
significantly different from zero (at the 5% level): ischaemic stroke and injuries and adverse 
effects for both genders; diabetes, haemorrhagic stroke and other chronic liver diseases for 
men only. In contrast, all the PAAFs were significantly positive for cancer.  
The non-adjusted PAAFs were lower than the adjusted PAAFs, except for ischaemic heart 
diseases for women. For cancer, the non-adjusted PAAFs were all positive, but not always 
statistically different from 0. For diabetes and ischaemic heart disease in both genders and 
ischaemic stroke for women, the PAAFs were negative. 
 
When the consumption data were adjusted for the 1986 rather than the 2002 alcohol sales 
data, the PAAFs were slightly higher, reflecting the higher consumption. 
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Setting the number of consumption categories to 4 or 10 instead or 6 did not change the 
main results. 
 
The breakdown of the PAAF by consumption-category for the non-adjusted data revealed 
that the protective effect of alcohol with regard to stroke was mainly observed for the first 
consumption category (< 20 g/day) (appendix, table 5). For the adjusted data, the greater 
part of the mortality for most of the diseases could be attributed to the highest consumption 
category (> 80 g/day) (appendix, table 6).  
 
Number of deaths and YPLL attributable to alcohol 
The total number of alcohol-attributable deaths for subjects aged between 15 and 75 years 
varied markedly, adjusted vs. non-adjusted data (7158 vs. 20255 deaths) (table 3). The 
corresponding proportion of total mortality (i.e. the total PAAF) varied from 4.0% for the non-
adjusted data to 11.3% for the adjusted data. The causes that contributed most to this 
difference were cancer, stroke, and liver cirrhosis. 
For subjects aged between 15 and 75 years, the total YPLL PAAF was similar to the total 
death PAAF for both genders and the adjusted and non-adjusted data. Thus, the age 
structures of alcohol-attributed mortality and general mortality were similar. 
 
For all-age mortality, the difference between the adjusted and non-adjusted numbers of 
alcohol-attributable deaths was greater. Moreover, the non-adjusted mortality attributable to 
alcohol was negative for women (-995 deaths), and the adjusted alcohol-attributable mortality 
(33356 deaths) was much greater than the mortality in the group aged between 15 and 75 
years. Mortality due to stroke, frequent in the elderly, accounted for most of the variations. 
All-cause approach 
When all-cause mortality was considered, adjustment of alcohol consumption data for 
alcohol sales appeared even more crucial than in the cause-specific approach (table 4). Non-
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adjusted alcohol-attributable mortality was strongly negative, with 23756 deaths of subjects 
aged between 15 and 75 years due to alcohol consumption avoided in France. The number 
of avoided deaths for men was higher than that for women. 
In contrast and in a manner more consistent with the cause-specific results, 15950 deaths of 
subjects aged between 15 and 75 years, mostly men, were found to be attributable to alcohol 
consumption when the adjusted consumption data were considered. 
For the all-age estimates, the difference between the non-adjusted and adjusted results was 
marked, with, respectively, 69154 deaths due to alcohol avoided versus 36843 attributed to 
alcohol consumption. The differences were observed for both the number of deaths and the 
YPLL. 
When the 'European countries' parameter estimates from the meta-analysis reported by Di 
Castelnuovo were considered, the PAAFs were lower overall, but with far larger confidence 
intervals, particularly for women. 
Similar results were obtained when the PAAFs were calculated using 4 or 10 consumption 
categories instead of 6. 
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Discussion 
Under the various hypotheses, the numbers of alcohol-attributable deaths exhibited marked 
variation. After adjustment of the alcohol consumption distribution for sales data, the number 
of alcohol-attributable deaths of subjects aged between 15 and 75 years, considered to be 
the sum of the cause-specific numbers of deaths, was 20255, equivalent to 11.3% of the 
overall mortality. Without adjustment for sales data, the number fell to 7158, equivalent to 
4.0% of the overall mortality. Using an all-cause mortality approach for subjects aged 
between 15 and 75 years, the consumption-adjusted number of alcohol-attributable deaths 
was 15950 (8.8% of total mortality). Strikingly, the non-adjusted estimate was found to be 
negative: -23756 deaths (-13.2% of total mortality). 
Other methodological considerations also influenced the results, but to a lesser extent. 
 
Alcohol consumption 
The analysis was restricted to the quantity of alcohol consumed without addressing the 
pattern of consumption. However, for many diseases, and particularly coronary heart 
diseases, the relative risks are highly dependent on both mean consumption and 
consumption pattern (37). While some studies have tried to take the frequency of alcohol 
consumption or binge drinking into account in the estimation of the burden of disease 
attributable to alcohol (2), this study was unable to identify compatible consumption data and 
relative risk estimates based on strongly established meta-analyses that did not only 
consider mean consumption. For similar reasons, smoking prevalence, which constitute a 
strong synergistic factor with alcohol for some cancers (38), was not considered either. 
The average consumptions derived from the 2002 ESPS and 2005 Health surveys are of the 
same order of magnitude as those in other studies (3, 6, 7, 24), but the coverage rate of the 
alcohol sales data is low compared to that of other estimates (39, 40). The protocols used to 
obtain the data are based on AUDIT-C methodology, which is used internationally to ensure 
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data comparability, with a quantity-frequency questionnaire addressing the preceding 12 
months. 
Considerable literature addresses the various sources of bias in alcohol consumption 
measurement (25). The quantity-frequency method, like many others (41), has its limitations 
and generally underreports the true consumption. This method is relevant for evaluating 
habitual drinking patterns, but leads to under-reporting of infrequent heavy drinking. 
Specifically for France, the alcohol consumption categories given in the questionnaire may 
be too low. The relative norm may tend to minimize reporting. It is also to be noted that, in 
the two overall population surveys, the questions on alcohol consumption were located in the 
middle of a large questionnaire, and this may have influenced the answers. 
The estimated average consumption is also influenced by the choice of the average amount 
of alcohol per drink. Usually, a glass of wine in French bars contains 12.5 cL of wine, 
equivalent to 10 g of pure alcohol per drink. While wine is still the main alcoholic beverage in 
France (42), the same 10 g standard is often used as an approximation for beer (25 cL) or 
spirits (3 cL) (43). The same standard has been used in other European studies (44, 45). 
However, the amount of alcohol per drink can vary greatly depending on the beverage (wine, 
beer, spirits, etc.), country or place of consumption (home vs. public) (44, 46). To the authors' 
best knowledge, no study has evaluated the real content of drinks in France. Given the inter-
country heterogeneity of the alcohol content of beverages (47), the 10 g conservative 
standard was selected. 
In any event, the cultural and social representations of alcohol consumption are influenced 
by the context, and reporting discrepancies between countries, genders, age groups and 
geographic areas (urban vs. rural, etc.) may be observed (48). 
 
Cause-specific vs. all-cause approach 
The adoption of a cause-specific approach or an all-cause approach has great impact on the 
estimates. The cause-specific structure of alcohol-attributable mortality is, in itself, 
informative. It also enables the various associations between cause-specific incidence and 
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alcohol consumption (e.g. J-shaped association for cerebrovascular diseases and linear 
association for some cancers) to be taken into account. 
The disease selection used in the cause-specific approach is not exhaustive. It is based on 
the current state of knowledge of the association between alcohol and the main causes of 
death. Thus, the cause-specific approach may provide greater confidence than the all-cause 
approach with regard to the relationship between alcohol consumption and the incidence of 
specific diseases considered causal: it is obviously harder to take into account the various 
confounding factor when considering all-cause mortality. 
The association between all-cause mortality and alcohol consumption has been well 
documented and many major possible confounding factors have already been taken into 
account, without dramatically changing the results (18). The association between all-cause 
mortality and alcohol aggregates many conditions that have not been considered yet and are 
potentially associated with alcohol consumption. In addition, the all-cause mortality approach 
avoids the potential bias due to the application of relative risks of incidence to mortality 
counts. 
However, the association between alcohol consumption and all-cause mortality may be 
influenced by the cause-specific structure of the reference (i.e. abstainer) mortality (24). 
Hence, contrary to the cause-specific approach, the all-cause approach assumes that the 
population of interest and the population from which the relative risks are derived have 
similar cause-specific mortality structures. In order to evaluate the potential bias this could 
imply on the estimation of the French PAAF, we considered the European specific estimates 
of the association, which included French studies (18). The estimates were then lower but of 
the same order of magnitude than the 'all-countries' estimates. 
Therefore, even if the cause-specific approach should be preferably used, the two 
approaches may be considered complementary rather than mutually exclusive. The 
difference between the two approaches is a means of quantifying the remaining part of the 
association between alcohol and mortality that has not been specifically identified. 
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Adjusted vs. non-adjusted consumption data 
General population surveys assessing alcohol consumption distribution in the overall 
population largely underestimate real alcohol consumption. The same issue may be 
encountered in epidemiological studies evaluating the relative risks in different countries. 
Therefore, the impact of the choice of adjustment for alcohol sales data is strongly 
dependent on the comparability of alcohol consumption levels between those two sources 
(27). 
The specific attention given to alcohol consumption in epidemiological studies may better 
minimize, but certainly not totally eradicate, under-reporting, as has been observed in French 
studies (49, 50). Thus, the adjustment is likely to reduce the gap between the two 
consumption data sources. The adjusted estimates constitute an upper limit of the ‘real’ 
value, which is closer to the values reported in previous studies in France (4, 5). Instead of 
the 100% coverage rate adjustment done in this study, an intermediate coverage rate leading 
to intermediate mortality estimates, could have been chosen (27). 
A more rigorous option would be to also address the coverage rate issue in meta-analyses. 
The distortion between general population surveys and epidemiological studies could be 
minimized by systematically adjusting alcohol consumption on the corresponding national 
alcohol sales data. 
The method used to adjust consumption data assumes that under-reporting is independent 
of the level of consumption, while not modifying the proportion of abstinence. This is a strong 
hypothesis. Similar proportions of abstainers were observed in this study and other French 
observational studies (49, 50). However, biases could derive from this choice. It is likely that 
the alcohol consumption of heavy drinkers is underestimated more than that of more 
moderate drinkers. The amount of pure alcohol per glass used in this study, 10 g, may be 
specifically underestimated for heavy drinkers (51). 
With a view to comparison, it is noteworthy that the French Ministry for Road Safety 
estimated the number of accidental deaths attributable to alcohol to be 861 (52). This 
estimate, using specific additional information, can be considered a gold standard. However, 
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not all alcohol-attributable violent deaths consist in road accidents. Therefore, the non-
adjusted number of alcohol-attributable violent deaths, 667 deaths for all ages, is clearly 
underestimated. However, it is difficult to determine whether the adjusted number, 3118 
alcohol-attributable violent deaths for all ages, is overestimated. Moreover, on the basis of 
the meta-analysis by Corrao (22), the relative risk of violent death as a function of alcohol 
consumption is probably the most culture- and country-dependent of all the relative risks 
available. Unfortunately, no independent PAAF estimates for violent assault or other types of 
injury are available. Had estimates been available, they would have been used instead of the 
general estimation method. 
 
Lag time between adjusted consumption data and mortality 
A lag time between alcohol exposure and chronic disease mortality is taken into account in 
some studies (4, 5), but more often is not (3, 6-8, 10, 53, 54). One component of the decision 
may reside in the short term associations between alcohol per capita and mortality for some 
chronic diseases in population time-series studies (55, 56). The results support the 
hypotheses of a short lag time between alcohol consumption and mortality from chronic 
diseases. However, as discussed in those studies, the associations are weak, and could be 
due to many other factors, including poor quality historical data. Specifically, for ischaemic 
heart disease, the population time-series method has been criticised (57). Other studies have 
not generated consistent results (58, 59). Generally, the lag time has been insufficiently 
documented in studies estimating relative risks. However, the sensitivity analysis in the 
present study only showed very slight changes in the results when time-lagged alcohol sales 
data were considered, despite the fall in alcohol sales in France between 1986 and 2006. 
 
The abstinence issue 
In this study, abstainers were considered to be the reference. Since many current prevention 
policies only focus on heavy or binge drinking, the results may not appear pertinent to policy 
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makers. However, abstention can also be viewed as a public health issue, and the results 
show that, with some hypotheses, abstention can even have a strong impact on mortality. 
The authors verified that the methodological issues addressed in this paper influenced the 
results in the same way when the reference group consisted in moderate drinkers and when 
it consisted in abstainers. 
According to recent results, the choice of the definition of 'abstainer' may have a marked 
impact on the evaluation of the risks related to consumption category for some diseases (20). 
However, those recent results are still under debate and the meta-analyses lack power in 
that the studies included were selected in a restrictive manner. Therefore, only meta-
analyses that employed a broad definition of 'abstainer' were considered in the study 
reported herein. 
 
The number of deaths attributable to a common environmental factor like alcohol is to be 
interpreted with caution. Some studies have reported positive overall mortality attributable to 
alcohol (3, 4, 9, 24), while another has reported negative mortality (8). 
The number of alcohol-attributable deaths varied greatly, depending on the hypothesis used. 
More realistic and evidence-based estimates seemed to be obtained by adjusting the 
consumption data for national alcohol sales, and by summing the cause-specific estimates. 
However, given the major influence of such results on public health decisions, it appears 
necessary to elucidate the question of the comparability of alcohol consumption data 
generated by general population surveys and epidemiological studies, and that of the gap 
between all-cause mortality and cause-specific incidence associations with alcohol 
consumption. 
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Figure 1  Prevalence of drinkers by amount of alcohol consumed in grammes of pure alcohol per day 
and by gender, adjusted or non-adjusted for alcohol sales data - ESPS 2002 survey 
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Table 1 Relative risks of various causes of death associated with alcohol drinking expressed in 
grammes of pure alcohol per day. 
Conditions (ICD 10 code) Ref. Gender 
Consumption category (grammes of ethanol per day) 
25 g/day 50 g/ day 100 g/ day 
RR [IC95%] RR [IC95%] RR [IC95%] 
C
a
n
c
e
r 
Oral cavity and pharynx (C01-C14) (12) Total 1.86 [1.76; 1.96] 3.11 [2.85; 3.39] 6.45 [5.76; 7.24] 
Oesophagus (C15) (12) Total 1.39 [1.36; 1.42] 1.93 [1.85; 2.00] 3.59 [3.34; 3.87] 
Stomach (C16) (11) Total 1.07 [1.04; 1.10] 1.15 [1.09; 1.22] 1.32 [1.18; 1.49] 
Colon (C18) (12) Total 1.05 [1.01; 1.09] 1.1 [1.03; 1.18] 1.21 [1.05; 1.39] 
Rectum (C20) (12) Total 1.09 [1.08; 1.12] 1.19 [1.14; 1.24] 1.42 [1.30; 1.55] 
Liver (C22) (12) Total 1.19 [1.12; 1.27] 1.4 [1.25; 1.56] 1.81 [1.50; 2.19] 
Larynx (C32) (11) Total 1.38 [1.32; 1.45] 1.94 [1.78; 2.11] 3.95 [3.43; 4.57] 
Breast (C50) (31) Total 1.25 [1.20; 1.29] 1.55 [1.44; 1.67] 2.41 [2.07; 2.80] 
Ovary (C56) (11) Female 1.11 [1.00; 1.24] 1.23 [1.01; 1.54] 1.53 [1.03; 2.32] 
O
th
e
r 
c
h
ro
n
ic
 d
is
e
a
s
e
s
 
Diabetes (E10-E14) (16) 
Male 0.73 [0.68; 0.80] 0.91 [0.80; 1.04] 1.64 [0.58; 4.67] 
Female 0.62 [0.57; 0.68] 0.88 [0.56; 1.41] 1.41 [0.21; 9.54] 
Hypertension (I10-I15) (12) Total 1.43 [1.33; 1.53] 2.04 [1.77; 2.35] 4.15 [3.13; 5.52] 
Ischaemic heart disease (I20-I25) (12) Total 0.81 [0.79; 0.83] 0.87 [0.84; 0.90] 1.13 [1.06; 1.21] 
Haemorrhagic stroke (I60-I62) (7) 
Male 1.40 [0.71; 2.73] 2.19 [1.47; 3.27] 2.67 [0.00; >1000] 
Female 0.62 [0.54; 0.71] 7.98 [3.25; 19.6] 26.31 [0.00; >1000] 
Ischaemic stroke (I63-I66) (7) 
Male 0.99 [0.85; 1.16] 1.33 [1.07; 1.66] 2.13 [0.02; 294.99] 
Female 0.61 [0.54; 0.68] 1.06 [0.36; 3.12] 2.11 [0.00; >1000] 
Liver cirrhosis (K70,K74.6) (12) Total 2.90 [2.71; 3.09] 7.13 [6.35; 8.00] 26.52 [22.26; 31.59] 
Other chronic liver diseases (K73-K74.5) (22) Total 1.20 [1.10; 1.50] 1.40 [1.20; 2.50] 2.00 [1.70; 5.70] 
Chronic pancreatitis (K86.0,K86.1) (12) Total 1.34 [1.16; 1.54] 1.78 [1.34; 2.36] 3.19 [1.82; 5.59] 
Injuries and adverse effects (V01-Y89) (22) Total 1.10 [1.00; 1.30] 1.10 [1.00; 1.70] 1.30 [1.00; 3.10] 
All cause mortality, 'all countries' (18) 
Male 0.91 [0.89; 0.93] 1.05 [1.03; 1.08] 1.41 [1.35; 1.47] 
Female 1.00 [0.91; 1.09] 1.30 [1.12; 1.50] 2.09 [1.61; 2.70] 
All cause mortality, 'European countries' (18) 
Male 0.80 [0.72; 0.89] 0.92 [0.78; 1.08] 1.22 [0.95; 1.56] 
Female 1.07 [0.55; 2.06] 1.53 [0.54; 4.37] 2.93 [0.55; 15.66] 
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Table 2 Population alcohol attributable fraction (%) by cause and by gender, for adjusted and non-
adjusted consumption data 
   Non-Adjusted data Adjusted data 
 Condition (ICD10 code) Male Female Male Female 
C
a
n
c
e
r 
Oral cavity and pharynx (C01-C14) 26 [24; 28] 10 [8; 12] 72 [69; 74] 38 [36; 41] 
Oesophagus (C15) 14 [12; 16] 5 [3; 7] 54 [52; 57] 22 [20; 25] 
Stomach (C16) 3 [1; 5] 1 [-1; 3] 13 [7; 18] 4 [1; 6] 
Colon (C18) 2 [0; 4] 1 [-1; 3] 9 [2; 15] 3 [0; 5] 
Rectum (C20) 3 [1; 5] 1 [-1; 3] 16 [12; 21] 5 [3; 8] 
Liver (C22) 7 [5; 9] 2 [0; 4] 28 [19; 35] 10 [7; 13] 
Larynx (C32) 14 [12; 16] 5 [3; 7] 58 [53; 62] 24 [21; 26] 
Breast (C50) 9 [7; 11] 3 [1; 5] 40 [33; 45] 14 [12; 17] 
Ovary (C56)    1 [-1; 3]     6 [3; 10] 
O
th
e
r 
c
h
ro
n
ic
 d
is
e
a
s
e
s
 
Diabetes (E10-E14) -14 [-22; -7] -18 [-24; -12] 17 [-3; 30] -17 [-28; -8] 
Hypertension (I10-I15) 15 [13; 18] 5 [3; 7] 59 [49; 66] 25 [21; 29] 
Ischaemic heart diseases (I20-I25) -5 [-8; -3] -2 [-4; 0] 2 [-2; 6] -4 [-7; -2] 
Haemorrhagic stroke (I60-I62) 13 [9; 18] -2 [-6; 1] 43 [-100; 72] 64 [38; 75] 
Ischaemic stroke (I63-I66) 1 [-2; 4] -13 [-15; -11] 32 [-83; 58] -8 [-37; 10] 
Liver cirrhosis (K70,K74.6) 50 [47; 52] 21 [19; 23] 92 [91; 93] 69 [66; 72] 
Other chronic liver diseases (K73-K74.5) 7 [4; 10] 2 [0; 4] 32 [-3; 49] 11 [5; 16] 
Chronic pancreatitis (K86.0,K86.1) 12 [9; 15] 4 [2; 6] 50 [23; 63] 20 [13; 25] 
Injuries and adverse effects (V01-Y89) 2 [0; 5] 1 [-1; 3] 11 [-16; 28] 3 [-1; 7] 
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Table 3 Number of deaths and YPLL attributable to alcohol consumption, by cause and by gender, for adjusted and non-adjusted consumption data 
  Not-adjusted data Adjusted data 
  Male Female Total Male Female Total 
Age Conditions (ICD10 code) Deaths YPLL Deaths YPLL Deaths YPLL Deaths YPLL Deaths YPLL Deaths YPLL 
15 
- 
75 
years 
Cancer             
Oral cavity and pharynx (C01-C14) 731 16 461 45 1 291 777 17 752 1 978 44 541 174 4 936 2 152 49 477 
Oesophagus (C15) 299 6 174 16 411 315 6 585 1 163 24 034 76 1 911 1 239 25 945 
Stomach (C16) 43 873 5 138 49 1 011 213 4 313 25 634 238 4 947 
Colon (C18) 52 963 11 266 63 1 229 253 4 704 50 1 177 303 5 881 
Rectum (C20) 32 627 5 120 37 747 157 3 070 23 548 180 3 618 
Liver (C22) 228 4 372 17 386 245 4 758 928 17 797 70 1 633 998 19 430 
Larynx (C32) 127 2 689 5 131 132 2 820 521 10 994 25 655 546 11 649 
Breast (C50) 9 172 203 5 576 211 5 748 37 751 938 25 758 975 26 510 
Ovary (C56)    25 615 25 615     115 2 824 115 2 824 
Diabetes (E10-E14) -284 -5 433 -212 -4 665 -496 -10 098 346 6 630 -207 -4 557 139 2 073 
Mental and behavioural disorders (F10) 2 226 60 211 536 16 955 2 762 77 166 2 226 60 211 536 16 955 2 762 77 166 
Degeneration of nervous system (G31.2) 64 1 396 13 364 77 1 760 64 1 396 13 364 77 1 760 
Alcoholic polyneuropathy (G62.1) 10 251 2 49 12 300 10 251 2 49 12 300 
Hypertension (I10-I15) 132 2 495 26 574 158 3 070 505 9 569 126 2 728 630 12 296 
Ischaemic heart diseases (I20-I25) -454 -9 191 -47 -1 062 -501 -10 253 197 3 987 -86 -1 923 111 2 064 
Alcoholic cardiomyopathy (I42.6) 72 1 753 10 318 82 2 071 72 1 753 10 318 82 2 071 
Haemorrhagic stroke (I60-I62) 251 5 503 -32 -831 220 4 672 794 17 394 868 22 791 1 662 40 185 
Ischaemic stroke (I63-I66) 24 434 -122 -2 581 -98 -2 147 613 10 892 -79 -1 667 534 9 226 
Alcoholic gastritis (K29.2) 5 162 0 0 5 162 5 162 0 0 5 162 
Liver cirrhosis (K70,K74.6) 2 293 52 990 370 10 330 2 663 63 319 4 254 98 297 1 240 34 603 5 494 132 900 
Other chronic liver diseases (K73-K74.5) 1 26 1 12 2 39 6 119 2 55 8 173 
Chronic pancreatitis (K86.0,K86.1) 9 216 0 11 9 227 35 886 2 53 37 939 
Injuries and adverse effects (V01-Y89) 367 12 260 43 1 520 410 13 780 1 772 59 209 185 6 509 1 956 65 718 
Total attributable to alcohol 6 237 155 403 921 29 929 7 158 185 332 16 148 380 962 4 107 116 354 20 255 497 316 
Total PAAF* 5.1 5.6 1.6 1.9 4.0 4.3 13.3 13.8 7.0 7.4 11.3 11.5 
All 
ages 
Total attributable to alcohol 7 352 164 813 -995 18 923 6 357 183 737 26 017 449 550 7 339 142 946 33 356 592 496 
Total PAAF* 2.7 4.3 -0.4 0.6 1.2 2.7 9.6 11.6 2.9 4.9 6.3 8.7 
 
YPLL: Years of potential life lost, calculated for each death as the life expectancy at the age of death 
*: Proportion of the total number of deaths or YPLL, respectively 
 
 27/29 
Table 4 PAAF, number of deaths and YPLL attributable to alcohol, calculated using the all-cause 
mortality approach 
 
 Age - Gender PAAF 
Number of 
deaths 
YPLL 
'all-countries' 
parameter 
estimates 
Non-adjusted data 
15 - 75 years - Male -13.3 [-16.2 -10.6] -16 165 -517 374 
15 - 75 years - Female -12.9 [-17.1 -9.0] -7 591 -377 860 
15 - 75 years - Total -13.2 [-15.0 -11.4] -23 756 -570 078 
All ages - Total -13.1 [-14.5 -11.8] -69 154 -895 233 
Adjusted 
15 - 75 years - Male 12.7 [9.4; 15.8] 15 422 350 992 
15 - 75 years - Female 0.9 [-3.7 5.1] 529 14 077 
15 - 75 years - Total 8.8 [6.9; 10.8] 15 950 365 068 
All ages - Total 7.0 [5.5; 8.5] 36 843 519 902 
'European 
countries' 
parameter 
estimates 
Non-adjusted data 
15 - 75 years - Male -22.2 [-27.6 -17.2] -26 859 -611 289 
15 - 75 years - Female -14.4 [-32.3 -0.7] -8 446 -224 946 
15 - 75 years - Total -19.6 [-24.3 -14.9] -35 305 -836 235 
All ages - Total -18.4 [-23.0 -13.8] -96 821 -1 280 061 
Adjusted 
15 - 75 years - Male 3.1 [-8.9 12.7] 3 765 85 691 
15 - 75 years - Female 7.6 [-28.1 27.7] 4 443 118 348 
15 - 75 years - Total 4.6 [-3.8 13.0] 8 208 204 039 
All ages - Total 5.3 [-2.5 13.1] 27 717 341 694 
 
 28/29 
Appendix 
Table 5 PAAF breakdown by consumption category, non-adjusted data 
      Consumption category 
Total 
   Abstinent 0 - 20 20 - 40 40 - 60 60 - 80 80 and + 
M
a
le
 
C
a
n
c
e
r 
Oral cavity and pharynx (C01-C14) 0.0 11.3 8.3 3.9 0.0 2.9 26.4 
Oesophagus (C15) 0.0 6.0 4.4 2.1 0.0 1.6 14.0 
Stomach (C16) 0.0 1.2 0.8 0.4 0.0 0.2 2.6 
Colon (C18) 0.0 0.9 0.6 0.2 0.0 0.1 1.8 
Rectum (C20) 0.0 1.6 1.1 0.5 0.0 0.3 3.4 
Liver (C22) 0.0 3.2 2.2 0.9 0.0 0.5 6.8 
Larynx (C32) 0.0 5.8 4.3 2.1 0.0 1.8 14.1 
Breast (C50) 0.0 4.1 2.8 1.3 0.0 0.9 9.1 
O
th
e
r 
d
is
e
a
s
e
s
 
Diabetes (E10-E14) 0.0 -11.4 -2.9 -0.1 0.0 0.5 -13.9 
Hypertension (I10-I15) 0.0 6.5 4.8 2.3 0.0 1.9 15.4 
Ischaemic heart diseases (I20-I25) 0.0 -3.6 -1.6 -0.3 0.0 0.1 -5.4 
Haemorrhagic stroke (I60-I62) 0.0 5.0 5.1 2.4 0.0 1.1 13.5 
Ischaemic stroke (I63-I66) 0.0 -1.3 0.9 0.9 0.0 0.8 1.3 
Liver cirrhosis (K70,K74.6) 0.0 17.1 14.7 8.8 0.0 9.1 49.6 
Other chronic liver diseases (K73-K74.5) 0.0 3.3 2.2 0.9 0.0 0.7 7.1 
Chronic pancreatitis (K86.0,K86.1) 0.0 5.3 3.8 1.8 0.0 1.4 12.3 
Injuries and adverse effects (V01-Y89) 0.0 1.1 0.8 0.3 0.0 0.2 2.4 
F
e
m
a
le
 
C
a
n
c
e
r 
Oral cavity and pharynx (C01-C14) 0.0 7.8 1.9 0.2 0.0 0.1 10.0 
Oesophagus (C15) 0.0 3.7 0.9 0.1 0.0 0.1 4.8 
Stomach (C16) 0.0 0.7 0.2 0.0 0.0 0.0 0.9 
Colon (C18) 0.0 0.5 0.1 0.0 0.0 0.0 0.6 
Rectum (C20) 0.0 0.9 0.2 0.0 0.0 0.0 1.1 
Liver (C22) 0.0 1.9 0.4 0.0 0.0 0.0 2.4 
Larynx (C32) 0.0 3.6 0.9 0.1 0.0 0.1 4.7 
Breast (C50) 0.0 2.4 0.6 0.1 0.0 0.0 3.1 
Ovary (C56) 0.0 1.1 0.2 0.0 0.0 0.0 1.4 
O
th
e
r 
d
is
e
a
s
e
s
 
Diabetes (E10-E14) 0.0 -17.0 -0.6 0.0 0.0 0.0 -17.6 
Hypertension (I10-I15) 0.0 4.1 1.0 0.1 0.0 0.1 5.3 
Ischaemic heart diseases (I20-I25) 0.0 -2.0 -0.3 0.0 0.0 0.0 -2.3 
Haemorrhagic stroke (I60-I62) 0.0 -5.0 1.0 0.9 0.0 0.7 -2.3 
Ischaemic stroke (I63-I66) 0.0 -12.4 -0.6 0.0 0.0 0.0 -12.9 
Liver cirrhosis (K70,K74.6) 0.0 15.1 4.3 0.6 0.0 0.6 20.7 
Other chronic liver diseases (K73-K74.5) 0.0 2.0 0.4 0.0 0.0 0.0 2.5 
Chronic pancreatitis (K86.0,K86.1) 0.0 3.3 0.8 0.1 0.0 0.1 4.2 
Injuries and adverse effects (V01-Y89) 0.0 0.6 0.1 0.0 0.0 0.0 0.8 
 
 29/29 
Table 6 PAAF breakdown by consumption category, data adjusted for 2002 alcohol sales data 
      Consumption category 
Total 
   Abstinent 0 - 20 20 - 40 40 - 60 60 - 80 80 and + 
M
a
le
 
C
a
n
c
e
r 
Oral cavity and pharynx (C01-C14) 0.0 2.3 4.8 2.9 16.4 45.0 71.5 
Oesophagus (C15) 0.0 1.7 3.5 2.1 12.2 35.0 54.5 
Stomach (C16) 0.0 0.6 1.2 0.6 3.2 7.5 13.0 
Colon (C18) 0.0 0.4 0.9 0.4 2.2 5.1 9.0 
Rectum (C20) 0.0 0.7 1.4 0.8 3.9 9.6 16.5 
Liver (C22) 0.0 1.3 2.6 1.4 6.8 15.4 27.6 
Larynx (C32) 0.0 1.5 3.2 2.0 12.4 38.4 57.6 
Breast (C50) 0.0 1.4 2.9 1.6 9.0 24.6 39.6 
O
th
e
r 
d
is
e
a
s
e
s
 
Diabetes (E10-E14) 0.0 -4.4 -3.9 -0.1 2.9 22.5 17.0 
Hypertension (I10-I15) 0.0 1.7 3.4 2.1 12.9 39.1 59.2 
Ischaemic heart diseases (I20-I25) 0.0 -1.8 -3.2 -0.5 -0.4 8.2 2.3 
Haemorrhagic stroke (I60-I62) 0.0 1.8 4.7 3.1 13.2 19.8 42.5 
Ischaemic stroke (I63-I66) 0.0 -0.5 0.3 1.1 7.4 24.0 32.3 
Liver cirrhosis (K70,K74.6) 0.0 1.4 3.1 2.6 18.6 66.3 92.1 
Other chronic liver diseases (K73-K74.5) 0.0 1.3 2.6 1.3 7.3 19.5 32.0 
Chronic pancreatitis (K86.0,K86.1) 0.0 1.6 3.3 1.9 11.2 32.4 50.4 
Injuries and adverse effects (V01-Y89) 0.0 0.5 1.0 1.4 1.7 6.8 11.4 
F
e
m
a
le
 
C
a
n
c
e
r 
Oral cavity and pharynx (C01-C14) 0.0 4.7 6.4 5.7 10.6 11.1 38.4 
Oesophagus (C15) 0.0 2.7 3.6 3.2 6.1 6.7 22.4 
Stomach (C16) 0.0 0.6 0.8 0.6 1.1 1.0 4.0 
Colon (C18) 0.0 0.4 0.6 0.4 0.7 0.6 2.8 
Rectum (C20) 0.0 0.8 1.0 0.8 1.3 1.3 5.2 
Liver (C22) 0.0 1.5 2.1 1.6 2.6 2.3 10.0 
Larynx (C32) 0.0 2.6 3.5 3.2 6.6 7.7 23.5 
Breast (C50) 0.0 1.9 2.6 2.1 3.8 4.0 14.3 
Ovary (C56) 0.0 0.9 1.2 0.9 1.6 1.6 6.3 
O
th
e
r 
d
is
e
a
s
e
s
 
Diabetes (E10-E14) 0.0 -13.5 -5.7 -0.5 0.4 2.2 -17.2 
Hypertension (I10-I15) 0.0 2.8 3.9 3.5 7.0 8.0 25.1 
Ischemic heart diseases (I20-I25) 0.0 -1.7 -2.4 -0.5 -0.2 0.8 -4.1 
Haemorrhagic stroke (I60-I62) 0.0 -1.5 -1.8 11.2 24.8 31.7 64.4 
Ischaemic stroke (I63-I66) 0.0 -10.4 -5.4 0.4 2.4 4.7 -8.3 
Liver cirrhosis (K70,K74.6) 0.0 5.1 7.0 8.6 20.6 28.0 69.3 
Other chronic liver diseases (K73-K74.5) 0.0 1.6 2.1 1.6 2.8 2.9 11.0 
Chronic pancreatitis (K86.0,K86.1) 0.0 2.4 3.3 2.8 5.4 5.9 19.7 
Injuries and adverse effects (V01-Y89) 0.0 0.5 0.7 0.5 0.9 0.8 3.4 
 
